摘要
The trial by Cano Contreras et al examined a proprietary formulation containing Silybum marianum and alpha-lipoic acid(SM-ALA),combined with a Mediter-ranean diet,in patients with metabolic dysfunction-associated steatotic liver disease.While some metabolic benefits were observed,limitations such as the absence of an SM-ALA-only group,the lack of histological data,and a small sam-ple size reduce the validity of the findings.Future research should follow clinical trial standards for pharmacological studies,including phase 1/2 testing,validated outcomes,and transparency.
